Focus and Scope
European Journal of Molecular & Clinical Medicine (EJMCM) is the official publication of the European Society for Translational Medicine. EJMCM publishes high quality manuscripts covering all aspects of molecular and clinical medicine. Submitted manuscripts are peer reviewed and selection is based on scientific excellence, distinctive contribution to knowledge and importance to the field. To provide a single platform for immediate dissemination of latest discoveries & developments from benchside and bedside, EUSTM has merged both of the Society’s journals; ‘New Horizons in Translational Medicine’ and ‘New Horizons in Clinical Case Reports’ into one publication: European Journal of Molecular & Clinical Medicine (EJMCM)
Molecular Medicine Section: Special consideration will be given to novel findings generated in cellular and molecular biology, genetics, stem cell biology, microbiology, immunology and the omics disciplines. In addition, quality manuscripts describing novel developments in the field of biomarkers, disease modelling, large data set mining will be considered for publication.
Clinical Medicine Section: Special consideration will be given to high quality clinical studies and case reports from all clinical specialties. Manuscripts should provide new insight and contribute to advance medical knowledge.
The journal is published online as a continuous volume and issue throughout the year. Articles are made available as soon as they are ready to ensure that there are no unnecessary delays in getting content publically available.
Special collections of articles are welcomed and will be published as part of the normal issue, but also within a separate collection page.
Open Access Policy
This journal operates at a Gold Standard level of open access. It provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. It complies with open access funding body policies and also encourages the publication of research data. There is no embargo on the journal’s publications. Submission and acceptance dates, along with publication dates, are made available on the PDF format for each paper.
Authors of articles published remain the copyright holders and grant third parties the right to use, reproduce, and share the article according to the Creative Commons license agreement.
Authors are encouraged to publish their data in recommended repositories. For a list of generic and subject specific repositories that meet our peer review criteria, see here.
The journal’s publisher focuses on making content discoverable and accessible through indexing services. Content is also archived around the world to ensure long-term availability.
Journals are indexed by the following services:
Articles that are NIH funded require the author to deposit the details in pubmed. Information on how to do this can be found here.
If the journal is not indexed by your preferred service, please contact us or alternatively by making an indexing request directly with the service.
The journal only displays advertisements that are of relevance to its scope and will be of interest to the readership (e.g. upcoming conferences). All advertising space is provided free of charge and the editor and publisher have the right to decline or withdraw adverts at any point. Advertisement in the Journal does not constitute on the part of the Publisher or the Society (EUSTM) a guarantee or endorsement of the quality or value of the advertised products or services described therein or of any of the representations or the claims made by the advertisers with respect to such products or services.
If you wish to propose a potential advert then please contact the editorial team. All advert images will have to be provided to the publisher.
No responsibility is assumed by the Publisher nor by the Society (EUSTM) for any injury and/or damage to persons or property as a result of any actual or alleged libellous statements, infringement of intellectual property or privacy rights, or products liability.
Annotation and post-publication comment
The journal platform permits readers to leave comments on the publication page, via the Disqus service. Readers will need a Disqus account to leave comments. Comments may be moderated by the journal, however, if they are non-offensive and relevant to the publication subject, comments will remain online without edit.
The journal platform also includes in-browser annotation and text highlighting options on full text formats via hypothes.is. Readers will require a hypothes.is account to create annotations, and will have the option to make these publicly available, available to a group, or private.